EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis

Gilwan Kim, Margaret Hoyt, Armen Zakharyan, Jennifer Durica, Alexandra Wallem, Lars Viktrup

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03072-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Gilwan Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN, 46285, USA. kim_gilwan@lilly.com. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Patient Acceptance of Health Care, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedPatient Acceptance of Health CareCalcitonin Gene-Related Peptide Receptor AntagonistsHumansRetrospective StudiesMaleFemaleMiddle AgedAdultUnited StatesAgedHealth Care CostsPiperidinesPyridines

Stichwörter der Autor:innen

CGRP mAbsCostsDiscontinuationGalcanezumabHealthcare resource utilizationMigraine preventionRimegepant

Substanzen

Antibodies, Monoclonal, Humanizedgalcanezumabrimegepant sulfateCalcitonin Gene-Related Peptide Receptor AntagonistsPiperidinesPyridines

Autor:innen und Institutionen

  • Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN, 46285, USA. kim_gilwan@lilly.com.
  • Eli Lilly and Company, 893 Delaware Street, Indianapolis, IN, 46285, USA.
  • TechData Service Company, LLC, 700 American Avenue, Suite 102, King of Prussia, PA, 19406, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Kim, G., Hoyt, M., Zakharyan, A., Durica, J., Wallem, A., & Viktrup, L. (2025). Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis. Advances in Therapy. https://doi.org/10.1007/s12325-024-03072-9

Vancouver

Kim G, Hoyt M, Zakharyan A, Durica J, Wallem A, Viktrup L. Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis. Advances in Therapy. 2025. doi:10.1007/s12325-024-03072-9

BibTeX
@article{Kim2025,
  author = {Kim, Gilwan and Hoyt, Margaret and Zakharyan, Armen and Durica, Jennifer and Wallem, Alexandra and Viktrup, Lars},
  title = {Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03072-9}
}
Kostenlos starten →